Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)
Pooling two trials, imatinib shrank tumours in about half of patients with locally advanced or metastatic dermatofibrosarcoma protuberans, confirming that blocking the PDGF receptor works in this fusion-driven sarcoma.
Overview
Pooled analysis of 24 patients with locally advanced or metastatic dermatofibrosarcoma protuberans treated with imatinib in the EORTC 62027 (800 mg) and SWOG S0345 (400 mg) phase 2 trials, both closed early for slow accrual.
Objective response was 46 percent, with median time to progression of 1.7 years, and responses were similar at both doses; tumours with fibrosarcomatous transformation also responded.
- Objective response 46 percent.
- Median time to progression 1.7 years; no dose-response difference between 400 and 800 mg.
Imatinib is the standard systemic treatment for unresectable, recurrent or metastatic dermatofibrosarcoma protuberans and is used neoadjuvantly to shrink large tumours before surgery.
- Small pooled cohort from two prematurely closed trials.
Similar pages
not linked directly; found by shared links- Key paperAALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children
Shares Journal of Clinical Oncology, Imatinib.
- Key paperKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour
Shares Journal of Clinical Oncology, Imatinib.
- Key paperImatinib for melanomas harbouring mutationally activated or amplified KIT arising on mucosal, acral and chronically sun-damaged skin
Shares Journal of Clinical Oncology, Imatinib.
- TargetPDGFRB
Shares Dermatofibrosarcoma protuberans, Imatinib.
- Key paperINTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib
Shares Journal of Clinical Oncology, Imatinib.
- TargetPDGFRA
Shares Dermatofibrosarcoma protuberans, Imatinib.